PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerAntonino Glaviano, Alan Prem Kumar, Aaron Song Chuan Foo et al.|Molecular Cancer|2023Cited by 1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W. Roberts, John F. Seymour, Monali Desai et al.|New England Journal of Medicine|2015Cited by 1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S. Davids, John F. Gerecitano, Andrew W. Roberts et al.|Journal of Clinical Oncology|2017Cited by 752
Small molecules, big impact: 20 years of targeted therapy in oncologyPhilippe L. Bédard, Lillian L. Siu, David M. Hyman et al.|The Lancet|2020Cited by 606
Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S. Davids, Robert J. Soiffer, Haesook T. Kim et al.|New England Journal of Medicine|2016Cited by 595